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Introduction
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Sickle-cell disease (SCD) is the most common genetic blood disorder, affecting millions
of people worldwide (1.2, 1.22). The disease results from a point mutation of glutamic acid to
valine in hemoglobin, the oxygen carrying molecule in erythrocytes (1.3). This mutation causes
red blood cells (RBCs) to stiffen into a sickled shape during de-oxygenation (1.3). Circulation of
sickled cells affects the vessels and associated tissues through which they flow. The harmful
mutation is kept in circulation because it confers some resistance to malaria when in the
heterozygous state (1.3). Issues like vaso-occlusion, occurring when sickled RBCs block blood
vessels, anemia, or a lack of hemoglobin in the blood, and raised hemolytic rate, or RBC lysis,
are common in SCD due to blockages and subsequent low oxygen levels in circulation (1.3). The
amount of debris in the blood that must be filtered out is drastically increased as a result of
sickled RBC hemolysis. Amassed hemolytic particles and circulatory system blockages
contribute to the formation of splenomegaly, or palpable enlargement of the spleen (1.4).
One of the main functions of a healthy spleen is to filter the blood, remove old
erythrocytes, and act as an immune center (1.5). In order for the spleen to function properly, it
needs to possess the appropriate cells, namely B and T cells, and internal structure, which is
organized into red pulp, where the blood is filtered; white pulp, which consists of lymphocytes;
and a marginal zone in between (1.5). With SCD, the spleen does not possess this orderly
structure (1.2). As a result, there is a decrease in baseline immunity associated with the
disease, specifically infection with Streptococcus pneumoniae (1.2). Anything that is present in
or travels through a SCD spleen is subject to its hostile environment caused by issues such as
hypo-splenism, splenic sequestration, and overall decreased functionality (1.4).
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In 1983, a new subset of innate-like B cells known as the B-1 cells were discovered in
mice by the Herzenberg lab (1.6). This group of researchers is one of the leading laboratories in
the fields of genetics and immunology. They have been curious about the development,
function, and life of the B-1 cells since their discovery (1.7, 1.8). This new B cell subset is
present mainly in the peritoneal and pleural cavities as well as the spleen (1.6, 1.9). B-1 cells
have been shown to develop earlier and have different stem cell origins than B-2 cells during
growth, theorized as either antigen-driven differentiation or following a layered immune
system model with distinct lineages/progenitors, (1.17), and secrete self- and poly-reactive
antibodies that form the natural antibody reserve in the absence of exposure to foreign antigen
(1.6). Naïve B-1 cells are present in the spleen and are sent to the peritoneal cavity upon
activation (1.6). To get to the spleen in a developed person, these IgM+ cells are first produced
in the bone marrow (1.17).
In mice, the B-1 cells can be recognized as either B-1a (CD5+) or B-1b (CD5-). The B-1a
cells are important first responders to pathogenic infection that produce natural low affinity
antibodies independently of B cell receptor (BCR) specificity which react to self-antigens and
help to clear apoptotic cells (1.6, 2.6, 2.27). Data has shown that these cells are mostly derived
from the fetal liver (0.1, 1.6). They then travel to the bone marrow where they develop without
T cell help, (4), traffic to their niche in the spleen and are sent to the peritoneal cavity upon
activation with antigen (2.27, 2.30). It is unclear if the seemingly self-maintained population of
B-1a cells have a correlation to adult bone marrow hematopoietic stem cells (HSCs) (1.6).
B-1b cells are uniquely T cell independent when it comes to their antibody production and have
a long-term effect after bacterial infection (1.6). Both B-1a and B-1b cells have been shown to
6

have particular roles in developing immunity to S. pneumoniae infections (2.5). Interestingly, in
SCD B-1a cells have been shown to be consistently diminished in the spleen, (1.2), but not the
peritoneal cavity of adult mice. A decrease in the number of B-1a cells is likely a contributor to
the increased susceptibility to infection associated with SCD (1.2).
The development of the immune system is an essential part of fetal growth. In SCD,
where components of the immune system do not function properly, it begs the question as to
what point in development this issue begins? Because of the intimate interactions between the
different systems of the body during development, it is crucial to draw parallels between
different fields in order to arrive at cohesive explanations for these anomalies. HSC niche
development and the correlations between the development of the neuroendocrine system
and immune system could provide crucial information to explain this aspect of SCD and will be
discussed in Chapters 1 & 2. SCD may cause a hostile environment for developing HSCs and/or
may have side effects within the neuroendocrine system, both of which could affect whether or
not the immune system develops properly.
Based on published data, I predict that B-1a cell numbers are lower in the SCD spleen
because of the hostile environment the cells have to develop in, rather than it being an innate
defect in the HSCs themselves. This hypothesis is the basis of the project conducted in Chapter
3 in an attempt to discern whether the B-1a cell diminution associated with SCD is an issue with
generation or activation. As HSCs progress from their multi-potent state to differentiated B-1
cells, development aspects like their induction and trafficking may be affected by the associated
symptoms of SCD. Experimentation has been done to determine whether or not there is an
innate defect in the adult bone marrow HSCs in terms of their ability to populate the lacking B7

1a cell niche in the SCD spleen (Ch. 3). Another method currently being utilized to gain more
insight regarding the B-1a cell diminution is BCR sequencing of the B-1a cells in the peritoneal
cavity. This method will reveal if the seemingly normal population of B-1a cells in the SCD
peritoneal cavity are more monoclonal, insinuating that the population of cells was derived
from a smaller number of precursors sent from the spleen. The results I have obtained with the
Szczepanek lab are bringing us closer to finding out the cause and implications of the B-1a cell
diminution in SCD.
The reason behind looking into the B-1a cell diminution in SCD is its potential effect on
the immune potential of those patients. As stated, patients with SCD have an increased
susceptibility to infection, especially with S. pneumoniae (1.2). Prevnar-13, the vaccine against
S. pneumoniae in children, has also been shown to have decreased efficacy long-term in SCD
mice (1.22; Appendix). The mechanism of the vaccine is unclear, but if B-1 cells have been
shown to play a role in defending against S. pneumoniae infection, (2.5), and have been shown
to be diminished in SCD, (1.2), then maybe the vaccine functions through a pathway involving
these cells. We set out to determine which B cell subsets respond to Prevnar-13 in SCD and
wild-type (WT) mice (Chapter 4) to see if there is a connection between the B-1a cell population
and the vaccine that could be affect the decreased efficacy.
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CHAPTER 1

Review: Hematopoietic
Stem Cells in Sickle Cell
Disease
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HEMATOPOIETIC STEM CELL DEVELOPMENT and EFFECTS IN VIVO
Hematopoiesis is seen as a “probabilistic stochastic process,” (1.11), that is
evolutionarily conserved and cycles through different areas of the mammal, going from the yolk
sac to the aorta-gonad mesonephros (AGM) region to the fetal liver and then finally to the bone
marrow (1.10, 1.11). Hematopoietic stem cell (HSC) numbers reach a maximum in the AGM
region directly prior to their presence in the fetal liver (1.12). The development of these cells
has a strong spatial and temporal correlation with endothelial cell development, leading some
to predict that the two cell types may arise from the same precursor cell (1.11). As the cells
migrate through these various embryonic niches, (1.14), they differentiate to different degrees
and move down distinct developmental pathways based on the context of inputs received,
varying from cell-cell interactions to cytokine signals (1.11). Even before HSCs commit to
becoming a certain cell type heterogeneity is seen between the stem cell fractions, making
them difficult to isolate in high purity (1.13). They differ in properties such as surface markers,
developmental potential, and cell cycle status depending on their age and their localization,
whether it be in the fetal liver or the bone marrow (1.10).
In order to maintain cell replaceability, HSCs need to reproduce to yield cells moving
further down the differentiation pipeline as well as stem cells with the capacity for selfrenewal. Their function may depend on their localization in specific bone marrow niches, which
can tend to be very hypoxic (1.10, 1.16). Long term (LT) reconstituting HSCs are present in adult
animals as a pool of renewable stem cells (1.11). Most adult HSCs in the bone marrow are
quiescent but will undergo lymphopoiesis to maintain homeostasis, although their division is
rare (1.10, 1.14). These multipotent cells are functionally influenced by Wnt/β-catenin and
10

Notch-Delta signaling pathways, where prolonged Wnt signaling could actually cause stem cell
exhaustion, (1.10), and Notch signaling induces the transcription of Runx1 for HSC activation
(1.11). HSCs have the capacity to produce more differentiated cell types; the developmental
pathways interwoven with lymphoid cells and their progenitors will be the focus of this review.
Lymphoid lineages can be derived from the LT reconstituting cells known as definitive HSCs
(1.11). Differentiation into lymphocytes occurs once the HSCs have migrated to the fetal liver
(1.10). Important genetic factors will assist in the driven differentiation of specific lineages, an
example being Runx1 HSC activation to form megakaryocytes and lymphocytes (1.10).
B and T lymphocytes are generated from a shared multipotent progenitor but are
derived from their own committed precursor cell lines and signaling cascades (1.10). B cell
activity is seen as early as 8-9 dpc in certain tissues (1.12). This time designation provides a
relative idea of just how early HSC migration to the fetal liver occurs because the cells do not
differentiate until they reach this point. Movement of cells to populate certain tissues may
occur by means of the circulatory system and by direct migration through tissue (1.10). The
circulatory system plays a crucial role the life cycle of HSCs and how their daughter cells affect
surrounding tissue. In SCD, HSCs have been shown to trigger remodeling of the perivascular
niche of the fetal spleen (1.19). Due to the altered circulation present in SCD, the
conformational change of the niche could cause the HSCs to have a problem with proliferation,
which could ultimately be the reason that B-1a cells are diminished in SCD. The blood supplies
cells with necessary molecules such as oxygen and glucose (1.15). During vertebrate
embryogenesis, it was shown that blood flow is also a pertinent player in HSC formation (1.15).
North et. al. depicted a directed correlation between the blood flow and number of HSCs
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present. Compounds shown to modify blood flow, such as nitric oxide (NO), affected HSC
induction after the embryo had developed a heartbeat, but NO donors regulated the number of
HSCs with or without blood circulation (1.15). NO has been established as a direct regulator of
vascular tone to increase vessel diameter, and thus increase the passage of total blood volume
(1.15). NO has now been pointed as factor in hematopoietic cluster formation and as a key
component of HSC production from the vascular niche after it was shown to be produced in the
endothelium of the AGM region upon interaction with blood flow (1.15). Increased vessel
diameter also directly corresponded to an increase in Runx1 expression, an important factor in
the formation of functional HSCs (1.15). If circulation ceased, HSC formation was impaired
(1.15). This link between blood flow in the developing embryo and the development of HSCs
could be a crucial point when thinking about immune cell development in SCD because
abnormal blood flow is characteristic of the disease.
A burning question that has been hovering around the field of developmental biology is
concerning the purpose of circulation and a beating heart at early stages in development when
diffusion is sufficient for oxygenation of developing tissue at the embryonic level (1.15). It may
be possible that blood flow is necessary to carry and deliver molecules and signals needed for
stem cells to differentiate properly, like VEGF, (1.14), and if blood flow is impaired, an issue
with activation and proper develop of the cells might be seen. When stem cells move towards
blood vessels, they are often on the road to differentiation (1.16). HSC niches in the bone
marrow tend to be very hypoxic. This low oxygen concentration in the bone marrow regulates
primitive hematopoiesis by preserving the stem-like character of HSCs (1.16). The blood of a
patient with SCD has lower oxygen levels comparatively because of the inability of sickled cells
12

to carry oxygen productively (1.3). A difference between the stem cell niche in the bone
marrow and the blood vessels that HSCs migrate toward is their oxygen level, so it may be
possible that the stem cells are not properly stimulated to differentiate in areas like the spleen
in SCD. Even after progenitors are committed, in order for maturation and proliferation to be
successful, a certain level of physiological oxygen concentration needs to be present (1.16).
The relationship between the embryo and the mother from which it is receiving all of its
nutrients can sometimes be overlooked. The placenta actually contains HSCs and other
multipotential progenitors, demonstrating the significance of the mother’s circulatory system
for the embryo’s development, especially in establishment of HSCs (1.14). The umbilical cord
allows HSCs to migrate between the developing embryo and the placenta for interaction with
the mother’s circulatory system (1.18). Once HSCs arrive at the fetal liver, they undergo varied
levels of expansion (1.18). This critical step in development could be impaired in SCD because of
possible pathology in the spleen even at early stages (Figure 3-3).
SCD has high levels of associated inflammation, as described, leading to increased
inflammatory signaling. It was noted that genes linked to innate immunity and inflammatory
signaling are enriched simultaneously in developing HSCs (1.20). This connection between
inflammation and innate immunity could lead towards uncovering why B-1a cells are
diminished in SCD. Inflammatory signaling is present during embryogenesis, notably in the AGM
region, and helps to regulate HSC development, often promoting survival and proliferation of
the stem cells (1.20). Innate immune cells secrete inflammatory cytokines as a method of
maintaining hematopoietic homeostasis so that the immune system is ready to defend the
body at any point. HSCs can actually respond directly to bodily harm, such as pathogenic
13

infection and endogenous ligands (1.20). In general, increased immune activation has the
potential to impair renewal of HSCs and lead to their exhaustion (1.21). Chronic activation of
the immune system in SCD could therefore have a cascade of negative effects.

DISCUSSION
Immune cell development is a finely intertwined process that incorporates many other
body systems. When so many components are involved, there are many aspects that can be
regulated, but that also means there are many areas where error can accumulate. After
becoming familiar separately with the literature surrounding B cell development and SCD, I
hypothesize that the functionality of immune cells will be altered and/or decreased in SCD
because of the hostile environment that the cells have to develop and be activated in. The main
alternative to this prediction is that decreased immune cell function is resultant from an innate
defect in the hematopoietic stem cells responsible for the defective immune cells in SCD.
To indicate whether or not the stem cells are defective themselves in SCD, competitive
experiments between SCD and WT cells could be conducted. One experiment would be to
create mixed bone marrow chimeric SCD:WT mice via bone marrow adoptive transfers in lethal
irradiated mice. This would reveal how the hematopoietic stem cells in a WT and SCD patient
may compare in their ability to generate differentiated immune cells. Ratios of SCD to WT
immune cells comparable to the ratios of stem cells implanted supports the hypothesis that
there is nothing innately wrong with the hematopoietic stem cells in SCD. The cell ratios would
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most likely have to be measure via analysis using Flow Cytometry. I have conducted this
experiment and the results are presented in Chapter 3.
In the event that there is an issue with the generation of the B cells in SCD because of an
innate problem with the hematopoietic stem cells, I would expect there to be a more
monoclonal population of differentiated B-1a cells in the peritoneal cavity because the B-1a
cells are diminished in the spleen but not the peritoneal cavity of SCD mice even though these
immune cells traffic from the spleen to the peritoneal cavity (unpublished). If there are
diminished B-1a cells in the spleen, where do the cells in the peritoneal cavity come from? Is it
possible that the cells that are present would be leaning towards a more monoclonal
population? In other words, are there a limited number cells being produced and sent to the
peritoneal cavity that then divide to fill in the niche that is meant to be filled with these B-1a
cells in SCD? This question of monoclonality can be tested using BCR sequencing of B-1a cell
DNA from the peritoneal cavity.
As stated, an associated symptom of SCD is increased susceptibility to infection. It is
possible that issues with hematopoietic cell trafficking and development in SCD are the cause.
Children with SCD are commonly put on prophylactic penicillin to prevent them from
contracting an infection with S. pneumoniae. Being prescribed a constant dose of a bactericidal
agent would kill both the bad and good bacteria present in the system, possibly causing a slew
of additional adverse side effects. Research with the microbiomes of specific diseases has
become popular, so it would be interesting to look into how this issue with hematopoietic stem
cell activation or generation cascades into an amplified range of other issues.
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Altered components of the circulatory system associated with SCD may provide the
knowledge necessary to explain why B-1a cells are diminished in SCD. In SCD, a physical change
in the shape of the HSC perivascular niche could affect how the cells are activated. Many of the
signals needed to keep HSCs in the pluripotent state or send them to be differentiated are
contained within the specific stem cell niche. If the HSC perivascular niche in the fetal liver,
arguably one of the most critical organs in HSC development, is altered in SCD, the activation
and differentiation of these cells could be highly compromised. The circulatory system is also
critical for transporting oxygen throughout the body, no matter what stage of development.
HSCs have a dichotomy in the oxygen levels of their niche and the blood to which they migrate.
In SCD, the decrease in oxygen carriers in the blood shortens the gap between the oxygen levels
in the niche and in circulation. If HSCs sense the difference in the oxygenation of their
environment as a signal to differentiate, then their potential activation could be affected in SCD
as a result.
As stated above, I am currently leaning towards the idea that the activation of HSCs is
impaired in SCD due to the resultant hostile in environment of the disease. Inflammation plays
a key role in hematopoietic developmental signaling and well as HSC activation in an adult. In
some cases, it promotes HSC proliferation. With the degree of inflammation and immune
activation that occurs in the SCD, the HSCs have a high chance of reaching the point of
exhaustion, stripping them of their ability to do their job and reform the appropriate
differentiated immune cells in the body. As inflammation is studied and HSCs themselves are
found to be able to defend the body against damage in SCD, whether it be from an exogenous
agent or an endogenous agent, it is becoming clear the amount of tasks that must be carried
16

out by this critical form of stem cells. Is it possible that all of the tasks delegated to HSCs are
split up like a pie chart? If one of the segments grows, another segment must shrink to
compensate. Relatively, is it possible that because the HSCs are busy defending against
inflammation and increase infection susceptibility in SCD, their potential to activate and
differentiate declines?
By conducting experiments, labs around the globe are hoping to find out just what
effect SCD has on the immune system in the host. I am hoping that the experiments that I have
designed are telling and will provide a clue into this search for an answer.
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CHAPTER 2

Review: Neuroendocrine
Control over Lymphoid
Hematopoiesis applied
to Sickle Cell Disease
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INTRODUCTION
Lymphoid hematopoiesis is the branch of immune cell development that stems from a
common lymphoid progenitor and results in the production of B cells, T cells, and Natural Killer
(NK) cells (2.3,2.7). B cells develop from hematopoietic stem cells (HSCs) in the bone marrow
following parturition and in the fetal liver before, and mature in both the bone marrow and the
spleen (2.3,2.4,2.7). To mature, they go through commitment, Ig repertoire formation, and
cellular selection (2.4). This whole process is highly regulated and yields two main subsets
known as the B-1 and B-2 B cells (2.4). B cells as a whole constitute the adaptive humoral
response (2.4). The B-1 cells are involved in the early response to pathogens, releasing natural
polyreactive antibodies in a more innate-like manner (2.5,2.6). T cells are also formed in the
bone marrow but mature in the thymus, where self-reactive cells are eliminated (2.3). Many
subsets of T cells are generated to act in the adaptive cell-mediated response, with the major
groups being helper T cells and cytotoxic T cells (2.3). NK cells, which function much less
specifically than B and T cells, also develop and mature in the bone marrow (2.3,2.7). NK cells
are members of the innate immune response (2.3).
The bidirectional communication between the neuroendocrine and immune systems
has been demonstrated as a crucial component of their individual operations (2.1). Both
afferent and efferent pathways have been discovered between structures that make up these
systems once they are matured (2.2). These interconnections are manifested through different
types of signaling, including antibody, antigen, electrical, and hormonal (2.2). Signals from the
neuroendocrine system to the immune system provide immunoregulation and enhance
immunospecificity, or the presence of high affinity cells, (2.2), but how early does this inter19

system communication begin? It is not a coincidence that the immune and endocrine systems
develop in a near parallel manner during early ontogeny (2.2). Many hormones and endocrine
factors have an effect on the development of the immune system, specifically lymphoid
hematopoiesis, from the onset of development, (2.2), (see Figure 2-1). In cases, like sickle cell
disease, (SCD), where the immune system functionality is dampened, in order to determine the
cause of the problem, it is important to take into account the components of the immune
system in addition to any processes that have a regulatory effect. This review will focus on the
effect of the neuroendocrine system on the immune system and its development. Correlations
will also be drawn to SCD and how the dampened immune response may be able to be
attributed to an endocrine disruption.

20

Figure 2-1: Besedovksy outlines the ontogenetic interactions between the immune and
endocrine systems (2).
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LITERATURE REVIEW
Lymphoid Hematopoiesis follows a series of events including differentiation, maturation
and activation, trafficking and programmed apoptosis (2.3,2.7). Apoptosis ensures that
lymphocytes only express function antigens and not self- or auto-reactive ones (2.18).
Apoptotic cascade factors are necessary for differentiation of HSCs into lymphoid and myeloid
lineages (2.18). Excessive pro-apoptotic factors during instances of stress can be detrimental to
the immune system as well. Hormones can have stimulatory or inhibitory effects on these
processes to help achieve the end goal of a mature immune system by maintain developmental
balance. Many lymphoid cells and their progenitors possess hormonal receptors (2.13).
Proliferation of T cells and production of antibodies by plasma cells are hormone dependent
(2.13). Without the hypothalamus, NK cells have minimal activity and blast transformation is
diminished (2.13). These effects and more are due to specific hormone effects on the immune
cells throughout the body. Non-stimulated immune cells are more easily influenced by
hormones so it is plausible to think that hormones would have prominent effects on progenitor
and other early cells (2.2). Major hormones that have been discovered as having effects on the
immune system and its development in normal and stressful situations will be discussed below.

STRESS IN THE IMMUNE SYSTEM
Stress was defined by Hans Seyle in 1974 as “the non-specific response of the body to
any demand imposed up on it” (2.24). Stress induces neuroendocrine hormone production,
specifically glucocorticoids and catecholamines (2.24). Normally, glucocorticoids are
immunomodulatory and anti-inflammatory but under stress conditions they become
22

immunosuppressive (2.24). With their increased levels, these hormones reduce NK cells
activity, lymphocyte proliferation, mitogenic blast transformation, lymphocyte populations by
apoptosis, and antibody production (2.1,2.8,2.11,2.13,2.24). Long-lasting stress responses early
in ontogenesis could cause homeostatic imbalances and leave an effect that is difficult to
reverse (2.14).

GROWTH HORMONE
Growth Hormone (GH) is a peptide hormone that is traditionally known the be released
by the somatotrophs of the anterior pituitary’s pars distalis (2.1,3,2.8). Its production is
pulsatile and primarily nocturnal (2.1). GH secretion by the pituitary is regulated positively by
growth hormone releasing hormone (GHRH) and negatively by somatostatin (GH-inhibiting
hormone), both of which are released by the hypothalamus (2.1,2.3,2.9). GH binding to its
receptor (GHR) causes dimerization of the GHR and a signaling cascade via the JAK-STAT
pathway (2.8,2.9) (Fig. 2-2). Upon binding of GH, a site for JAK-2 to bind is created on the GHR
(2.8,2.9). JAK-2, being a tyrosine kinase, phosphorylates its own tyrosine residues to provide a
binding site for STAT via its SH2 domain (2.8,2.9). JAK-2 will also phosphorylate the tyrosine
residues on STAT to activate the proteins and continue the cascade towards controlling gene
transcription (2.8,2.9). GH can also cause recruitment of focal adhesion kinase (FAK), Ras and
Raf, phosphatidylinositol-3 (PI-3) kinase, Akt/protein kinase B, MAPK, phospholipase C (PLC),
PKC and others to JAK-2 for multiple pathways to be activated depending on the cell type (2.8).
The effects of GH in pro-B cells and HSCs are mediated by the PI-3-kinase/Akt pathway and via
the NF-κB transcription factor (2.8) (Fig. 2-2). Bcl-2, an anti-apoptotic protein, is expressed in
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pro-B cells and HSCs by this pathway (2.8). Many cytokines also signal through these pathways
so there is speculation of cross-talk between GH and different cytokines (2.9). The human GHR
has been shown to have no sequence homology to other known kinases in its area of the
cytoplasmic membrane, (2.9), so if cross-talk were to be occurring it would need to be
downstream of the initial binding. Supporting the idea of cross-talk, it was shown that
inflammatory cytokines, such as IL-6 or TNFα, are able to stimulate feedback mechanisms that
also effect GH (2.9). Also, GH can provide negative feedback for prolactin (PRL) because it
signals through JAK-STAT and insulin-like growth factor (IGF-I) and because it uses a receptor
tyrosine kinase (RTK), both of which will be discussed later on (2.9).

GH EFFECT ON IMMUNE CELLS
GH has a widespread effect on the body’s systems including the immune system. NK, T
and especially B cells, express the GHR and act as targets for GH (2.8,2.9,2.11). GH can also be
produced by cells of the spleen, bone marrow, and thymus (2.8,2.12). GHRH and somatostatin
have also been detected in human lymphocytes (2.12). Consequentially, autocrine/paracrine
signaling of GH has been proposed within the lymphoid tissue, (2.8), including bone marrow,
spleen, thymus, lymph nodes, and tonsil (2.12). The local production could be compensating for
a lack of this apparently crucial endocrine hormone (2.12). In general, GH promotes cell cycle
progression and is a negative regulator for apoptosis, but it also has specific effects on immune
tissues (2.8). GH is one of the hormones capable of increases the immune response and it does
so in part enhancing MHC reactions (2.12,2.13). It is proportionate in circulation to the numbers
of B and T cells (2.13). In mice defective in the production of GH, (Snell dwarf mice or
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hypophysectomized mice), lymphocyte development and functioning were less than optimal,
especially with NK and T cells, and thymic atrophy was observed leading to immunodeficiency
(2.8,2.11,2.13,2.23). These phenotypic abnormalities were able to be rescued by exogenous GH
administration, (2.8,2.11), causing an increase to thymocyte, T cell and B cell numbers as well as
the size of the thymus, liver and spleen (2.7,2.13) (study rev. in Clark 1997). In another study, a
deficiency in GH lead to decreased amounts of B cell precursors (2.23). Even though this was
the case, GH itself is not an obligate thymopoietic or B-lineage immunoregulatory hormone,
(2.7), because many of its functions are carried out by induction of IGF-I (See IGF-I). GH
promotes T cell proliferation by stimulating DNA-synthesis and somatostatin inhibits mitogen
induced T cell proliferation (2.8,2.13). GH has also been shown to have the capacity to reverse
CD4+ and CD8+ T cell deficiencies (2.10) (See IGF-I).

GH ROLE IN STRESS RESPONSE
Stress causes changes to the body that may be harmful to its systems. GH and IGF-I are
two of the hormones that may be able to counteract negative immunoregulatory signaling
during stress manifested by glucocorticoids, (2.7,2.12), by exerting its own protective
immunoregulatory effect (2.8). Stress conditions induce apoptosis and GH is able to partially
protect immune cells from this detrimental outcome (2.8). Inflammatory cytokines also cause
stress on the body (2.9). SOCS, (suppressor of cytokine signaling), regulates cytokine levels in
immune tissues (2.9). Like STAT in the GH signaling cascade, SOCS also has a SH2 domain (2.9).
Proteins produced by the GH cascade are therefore able to interact with SOCS, stimulating its
production and providing GH with another way to protect immune tissue from damage (2.9). A
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drawback of the presence of SOCS is that if levels are too high, it could cause stunting of the
immune system’s development by blocking cytokines (2.9). Because the cascades of SOCS and
GH are interrelated, SOCS is able to feedback inhibit GH to keep the levels of both GH and SOCS
in check (2.9).
______________________________________________________________________________

Figure 2-2: Jeay shows GH effects on pro-B cells. (8)
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INSULIN-LIKE GROWTH FACTOR – I
Insulin-like growth factor - I (IGF-I) is a protein hormone that is produced following GH
stimulation in the liver and immune tissues, namely the thymus (2.3,2.7,2.12). Macrophages are
the greatest sources of IGF-I in immune tissues (2.10). Many of the effects of GH are achieved
through induction of IGF-I, (2.7), which includes growth and cell number increase as evidenced
by ‘growth factor’ in its full name. IGF-I is found bound to its designated binding proteins
(IGFBPs) when in circulation. The IGF-I receptor (IGF-R) is a RTK that also binds insulin (2.3,2.12)
(Fig. 2-3). It proceeds through the Shc/Grb2/MAPK pathway as well as the IRS/Akt/PI-3-kinase
pathway (2.15) (Fig. 2-3).

IGF-I EFFECT ON IMMUNE CELLS
GH and IGF-I can stimulate general immune cell function (2.1,2.7). It was shown that
together they can increase thymic, splenic, and bone marrow cellularity by both enhancing
survival and inducing proliferation of the lymphoid cells (2.1,2.7,2.10,2.12). IGF-Rs have been
found on erythrocytes, monocytes, B lymphocytes and T lymphocytes and in particularly high
quantity on NK cells and CD4+ T-helper cells (2.15). GH and IGF-I can induce clonogenesis of T
lymphoblasts, (2.10), and antigen-responsive B and T cells, increasing the number of responsive
cells (2.7). In cases of thymocyte deficiency, the combination of GH and IGF-I can provide repair
(2.14). GH and IGF-I are able to cooperate with cytokines, like GM-CSF, to help promote
hematopoiesis (2.1). These cytokines, those involved in inflammation, GH and IGF-I mutually
regulate each other to ensure that the developmental processes remain balanced (2.1,2.7).
They are also able to increase the release of IgG and IgE, which are antibodies necessary for the
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humoral immune response (2.10). IGF-I is able to indirectly initiate immunoglobulin gene
rearrangement and expression of antibodies like IgM as well by acting as a differentiation signal
for pro-B cells to mature into pre-B cells (2.10,2.12). With IGF-I present, B cells showed
enhanced antibody response as well (2.12).
IGF-I is recognized as an important survival, proliferation, and differentiation factor for
HSCs (2.10,2.15). IGF-I also functions by preventing apoptosis in HSCs (2.10,2.15). An increase in
IGF-I could lead to elevated lymphoid hematopoietic progenitor cell activity or number in the
bone marrow (2.10). Conversely, a deprivation of IGF-I can lead to HSC apoptosis (2.10).
Because IGF-I requires IGFBPs to remain present in circulation, HSCs will actually secrete these
binding proteins to ensure that there is enough IGF-I present (2.12). IGF-I produced by bone
marrow stromal cells is a potent B lymphopoietic factor as well (2.15). It acts to suppress cell
death signals sent to pro-B cells in conjunction with R-Ras (2.15). IGF-I works together with IL-7
to stimulate proliferation of pro-B cells (2.15). IGF-I has also been shown to stimulate CD4+ Thelper cells and splenic B cells to proliferate (2.15).
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Figure 2-3: Zumkeller shows the IGF receptor schematic and a portion of its
associated signal cascade. (15)
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PROLACTIN
Prolactin (PRL) is a protein hormone with many functions and is best known as being
released from the anterior pituitary (2.3,2.7). The PRL receptor (PRL-R) is similar to the GHR in
that it dimerizes in the membrane upon binding and signals through the JAK-STAT cascade (2.3).
Because of this similarity, human GH is able to bind and activate the PRL-R (2.7).

PRL EFFECT ON IMMUNE CELLS
PRL is a hormone, like GH, that increases the immune response (2.12,2.19). Snell dwarf
mice, which lack PRL, show flaws with their lymphocyte development and function (2.1). PRL-R
is expressed in peripheral blood lymphocytes, thymocytes, HSCs, stromal cells of the bone
marrow and thymus, and cells that mediate natural immunity, including NK cells, (2.7,2.9), but
is most prominent in B cells (2.12). PRL stimulates antibody production by B cells, (2.13), but is
not required for B cell development (2.7). This hormone can stimulate lymphocyte proliferation
but is not an obligate thymopoietic hormone (2.7). Also, PRL administration does not affect the
activity of CD4-/CD8- thymocyte populations, meaning it may not have a hand in the entire
developmental process (2.7). Because of the presence of the PRL-R on HSCs, PRL may have a
direct or indirect effect on early lymphoid hematopoiesis (2.7).

PRL ROLE IN STRESS RESPONSE
Stress causes immunosuppressive/anti-inflammatory signals and apoptosis of lymphoid
cells due to excess glucocorticoids (2.7). Glucocorticoids bind to cytoplasmic receptors (GR)
(2.7). The newly formed complex recognizes its DNA motif, glucocorticoid response element
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(GRE), which activates STAT-5 (2.7). Upon activation, STAT-5 binds the glucocorticoid-GR
complex and inhibits GRE as a negative feedback (2.7). Simultaneously, STAT-5 is required for
the PRL response and ends up enhancing the PRL cascade (2.7). By these means, PRL may be
able to counteract the effects of stress in immune tissues (2.7). Therefore, stress induces
release of PRL, which is speculated to assist in maintaining the immune system (2.7). In tissues
like the skeletal muscles and the liver where glucocorticoids are necessary to mediate
metabolism, PRL-R are not common so that the response is not dampened (2.7). The immune
tissue expression of PRL-R with GR protects it from negative manifestations of chronic stress,
like the degeneration of the immune response (2.7).

THYROID HORMONES
Thyroid hormones (TH), T3 (triiodothyronine) and T4 (thyroxine), are amino acid –
derived hormones produced in the thyroid gland following stimulation by thyroid stimulating
hormone (TSH) from the anterior pituitary (2.7). The function of THs is to regulate protein
expression and cell cycle progression, but it is also known to act on the development and
function of the immune system (2.7,2.13). The TH receptor (THR) is a nuclear receptor that is
bound to a corepressor in its resting state and represses DNA regions known as thyroid
response elements (TREs) (2.16,2.17). Upon binding of T3, a conformation change in the THR
that displaces the corepressor and recruits a coactivator to activate transcription of the TREs
(2.16,2.17) (Fig.2-4).

31

TH EFFECT ON IMMUNE CELLS
Even though THs may stimulate thymocyte proliferation, it has been shown that THs are
not necessary for thymopoiesis (2.7). THR is abundantly found on lympho-hematopoietic cells
(2.7). Instead of T cells, TH is needed for primary B cell development (2.7). If TH is not present,
the numbers of B lineage cells in the bone marrow were significantly decreased due to
decreased survival and lower rate of proliferation (2.7). A lack of TH also causes depressed
humoral and cell-mediated immunity as well as involution of the spleen and lymph nodes (2.7).
In line with the previous statements, hypothyroidism is correlated with arrested T and B
lymphopoiesis (2.7,2.14). Not much is known about the effect of TH on NK cells, but it has been
shown that TSH increases NK cell numbers in circulation (2.1). TH is may also play a role in
counteracting negative immunoregulatory signals and the negative effects of stress but this has
yet to be described (2.7).
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Figure 2-4: Dayan and Panicker provide a schematic for the cascade leading up
to TH action. (17)

33

ARGININE VASOPRESSIN
Arginine vasopressin (AVP) is a peptide, neurohypophyseal hormone that is produced in
the hypothalamus and released into the blood by the posterior pituitary (2.14,2.19). It is
released as early as prenatal ontogenesis (2.14). AVP is known for its antidiuretic function and
as a vasoconstrictor, but it should also be considered a neuroendocrine regulator of the
immune and inflammatory responses (2.19).

AVP EFFECT ON IMMUNE CELLS
AVP works together CRH to cause the release of adrenocorticotropic hormone (ACTH)
from the pituitary (2.19). ACTH stimulates the release of corticosteroids from the adrenal
glands which function to inhibit cytokines, so AVP indirectly decreases inflammation (2.19). The
receptor of AVP is also known to be present on inflammatory cells, human peripheral blood
mononuclear cells, and splenic lymphocytes so it can have a direct effect (2.19). AVP can
modulate the fever response and increase the power of primary antibody responses (2.19). In
the event that corticosterone levels are low with high AVP levels, inflammation is favored and
T-helper cell development is enhanced (2.19). This has been shown in cases of chronic
inflammatory disease where AVP levels are high in the plasma and hypothalamus (2.19). For the
opposite case where there is an AVP shortage, thymic and splenic involution are accelerated,
lymphocyte numbers in the blood decrease, and general immunity is depressed (2.14).
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SEX HORMONES
The major sex hormones are the steroid hormones estrogen and testosterone (2.3,2.2022). Both estrogen receptors (ER) and androgen receptors (AR) are nuclear receptors that affect
gene activation (2.3,2.20-22).

SEX HORMONES’ EFFECT ON IMMUNE CELLS
ERs and ARs are expressed on progenitor and mature immune cells, (2.1), as well as
accompanying stromal cells (2.22). Their steroid hormones therefore have the capacity to affect
the development and function of these cells (2.1). In comparison with males, females, who
have higher innate levels of estrogen, have more pronounced humoral and cell-mediated
immune responses, (2.21), especially during their reproductive years (2.1). Sthoeger
summarized these alterations to include elevated immunoglobulin levels, general decreased
susceptibility to infection, increased antibody formation following immunization, and graft
rejection rate differences (2.21). Both enhancing and suppressing effects are observed upon
addition of estrogen and testosterone to a culture of peripheral blood mononuclear cells
(PBMCs), consisting of B, T, and NK cells as well as monocytes (2.21). Very early lymphoid
progenitor cells have indeed been shown to be controlled in part by estrogen, showing that
estrogen it participates in bone marrow development and acts as a negative regulator of
lymphopoiesis (2.14,2.20). Lymphoid progenitor cells were depleted in mice treated with
estrogen, meaning that the progenitors for T, B, and NK cells were specifically targeted (2.20).
Estrogen and testosterone also have the potential to increase B cell differentiation of PBMCs,
(2.21), most likely by depleting the pro-B cell populations (2.20). This was tested in part by
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measuring the frequency of B220+ cells after estrogen treatment (2.20). Likewise, estrogen
deficiency was correlated with T cell loss and a decrease in inflammatory cytokine levels (2.22).
Gonadotropin-releasing hormone (GnRH), which is released from the hypothalamus and
indirectly stimulates production of sex steroid hormones, has also been shown to regulate
immunity during ontogenesis (2.14). Prior to birth, if GnRH signaling is blocked, thymocytes are
unable to proliferate or become activated by antigen (2.14). As current research stands, it
seems as though estrogen enhances mature immune cells and suppresses lymphoid progenitor
cells.

APPLICATION TO SICKLE CELL DISEASE
Many stresses are associated with sickle cell disease (SCD) (2.25). The sickled red blood
cells can cause issues like vaso-occlusion, anemia, increased hemolysis, and splenomegaly
(2.25). This stress could be a cause of the increased susceptibility to infection seen associated
with the disease (2.27,2.29). As aforementioned, glucocorticoids become immunosuppressive
under stress conditions (2.7,2.24). One large stress inducer in SCD is a zinc (Zn) deficiency
(2.28,2.29). Zn is critical for many enzymes and Zn-dependent transcription factors (2.29). Zn
deficiency leads to quickly diminished humoral and cell-mediated responses and lymphopenia
in circulation as a result of B and T cell precursor losses in the bone marrow, 40-80% (2.29). Zn
deficiency induces glucocorticoid production and glucocorticoid-mediated apoptosis,
disallowing normal levels of lymphopoiesis and specifically depleting the B cell compartment
(2.29). Zn supplementation to SCD patients increased multiple components of the immune

36

system and decreased oxidative stress, infection incidence, and generation of inflammatory
cytokines (2.28).
During development, the hormones in milk could be enough to allow the production of
normal lymphoid cells, (2.23), but when this natural supplementation is no longer available,
neuroendocrine hormone effects could serve as the immunoregulators necessary to push for
normal immune homeostasis because all of the major hormones discussed played a role in
stimulating the immune system (GH, IGF-I, PRL, TH, AVP, and sex steroids). But importantly, the
stresses caused by SCD could begin prior to birth because it is a genetic disease and cause
homeostatic imbalances with these hormones (2.14). The interwoven nature of the
neuroendocrine system with immune system is promising for unraveling the workings of the
immune systems in SCD and looking into these connections could yield treatment ideas for the
manifestations of SCD.

DISCUSSION
The focus of this review was the unidirectional communication from the
neuroendocrine system to the immune system with a focus on development. The
bidirectionality of the communication between the two systems should not be overlooked but
was outside of the scope of this review. Cytokines and hormones produced by immunes cells
themselves have just as important of a role regulating the neuroendocrine system as the
reverse. A lack of antigenic challenge was correlated with not only underdevelopment in the
lymphoid tissue but also an altered endocrine state (2.2).
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The interconnectivity of the immune and neuroendocrine systems provide potential
avenues for intervention in cases where one is not functioning properly, like with SCD. Each
hormone discussed in this review had an immunostimulatory effect, whether it be direct or by
negatively regulating immune dampeners. Also, each hormone aside from AVP was shown to
have a positive effect on lymphoid hematopoiesis at some point during development. These
hormones and others in addition to new factors, like microRNAs, (2.34), should have their levels
tested in certain disease states to discover possible supplementation therapies. Additional
studies need be conducted to conclude where hormones fit in when thinking of cell lineages
and developmental differentiation. Even though there is evidence for the necessity of some
hormones in early development, more controlled cases need to run to be sure of the entire
effect.
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CHAPTER 3

Personal Research: B-1a
Cell Diminution in Sickle
Cell Disease Spleen – An
Issue of Generation or
Activation
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INTRODUCTION
It has been shown that B-1a cells are diminished in the spleens of transgenic SCD mice (1.2).
B-1 cells play a role in developing immunity to Streptococcus pneumoniae and that patients
with SCD have a decreased baseline immunity, especially to S. pneumoniae (1.2, 1.6). Is it
possible that the diminution in B-1a cells is one of the reasons behind the decreased immunity
in SCD? If this is a possible effect of the diminution, are there other effects as well? In order to
eventually determine the potential effects of the B-1a cell diminution associated with SCD
spleen, we sought to find out why the B-1a cells are diminished in the first place. We tested
different aspects of their development to try and determine when they are affected. This is to
solidify if the B-1a cell diminution is an issue of generation of the cells from early on or from
activation in the hostile environment of SCD. Because their developmental pathway goes from
the fetal liver to the bone marrow to the spleen and then to the peritoneal cavity and
occasionally back to the spleen, (1.6), we decided to conduct tests for the capacity of the HSCs
in the adult bone marrow to produce B-1a cells and the B-1a cell numbers in their other main
terminal niche, the peritoneal cavity. Based on published data and our previous data, we
hypothesized that B-1a cells and diminished in the SCD spleen because they have to develop in
a hostile environment rather than there being an innate defect in the stem cells. In terms of
trafficking, B-1 cells appear to traffic from the spleen to the peritoneal cavity during
development (1.2, 1.6). Also, if the cells are exposed to antigen only in the peritoneal cavity
then they will remain and proliferate but if that antigen exposure is accompanied by
inflammation in the peritoneal cavity, the cells will travel to the spleen to become plasma cells
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(1.6). Given this information and our previous data, we expected to see a similar diminution of
B-1a cells associated with the peritoneal cavity as with the spleen in SCD.

MATERIALS AND METHODS
Animal Research Ethics Statement
This study was carried out in strict accordance with the recommendations in the Guide for the
Care and Use of Laboratory Animals of the National Institutes of Health. The protocol was
approved by the Institutional Animal Care and Use Committee at the University of Connecticut
(protocol #A14-029). Following irradiation, mice were weighed daily and monitored for signs of
distress. Mice that were determined to exhibit moderate to severe clinical signs were
considered for euthanasia via an overdose of carbon dioxide followed by cervical dislocation.

Mice
Two to three month-old mice harboring knock-ins of the human alpha globin transgene, along
with either a normal human beta globin or sickle beta globin transgene [B6;129Hbatm1(HBA)Tow Hbbtm2(HBG1,HBB)Tow/Hbbtm3(HBG1,HBB)Tow/J; stock number 013071]
were purchased from Jackson Laboratories. Mice homozygous for the normal human beta
globin transgene are henceforth referred to as wild-type (WT) mice and those homozygous for
the sickle beta globin transgene are referred to as SCD mice.
Two to three month-old wild-type C57BL/6 congenic mice [B6 CD45.1, PepBoy; stock number
002014] were purchased from Jackson Laboratories. These mice carry the differential Ptprc a
pan leukocyte marker, and will be referred to as CD45.1 mice.
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Irradiation
Irradiation was conduction on the WT recipient mice using a 137-cesium source (gamma
radiation levels at time of use: 11,576 R/hr) for 8 min each (1543.47 R total exposure). The
literature has shown doses of greater than 700 R to successfully ablate the bone marrow, (3.2),
which was the intended purpose of the irradiation in this experiment. Mice were weighed prior
to irradiation and were monitored and weighed daily for two weeks afterwards, which is the
approximate duration of potential irradiation sickness (Figure 3-1). Irradiation sickness causes
dehydration, difficulty eating dry food, and weight loss. The mice were given wet food, which
was changed daily and allowed them to eat more easily. If the mice achieved their weight prior
irradiation and no longer showed clinical signs then the transfer was deemed a success.

Weight (g)

Portions of protocol adopted from previous work by Cui and Duran-Struuck (3.1,3.2).

22
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0

5

10
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Days Post Adoptive Transfer
Figure 3-1: Weight vs. days post adoptive transfer – Data from one mouse for each group
(experimental & control) displayed to show the weight loss the then regain by the end of the
two week irradiation sickness period.
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Bone Marrow Extraction
Bone marrow contained hematopoietic stem cells was collected from the femurs of donor
CD45.1 and SCD mice and pooled respectively (WT marrow was used in place of SCD for control
mice). The femoral extraction protocol was extrapolated from multiple well established
techniques (3.3-3.6). Both end of the femur were removed using a scalpel and forceps on a hard
surface, being careful not to crack the bone in any other places. Bone marrow was then pushed
through the femur using sterile PBS loaded into a 1 mL syringe with a 25 gauge needle into a 1.5
mL microcentrifuge tube. To ensure the majority of the cells are released from the cavity, the
needle was also run around the inside of the cavity. Once pooled, the cell suspension was run
through the needle a few times to ensure that the trabeculae were broken up and the cells
were released into suspension.

Chimera Development
Bone marrow cells were counted using a hemocytometer and Trypan Blue to ensure only live
cells were counted. The 9:1 chimera (CD45.1:SCD) was made using the acquired numbers and
suspension volumes (and CD45.1:WT for controls). The chimera was then spun down at 300 rcf
for 5-10 min and resuspended with sterile PBS at a (5x106-1x107cells/100 µL) concentration
with the appropriate number of doses (100 µL/recipient) for slight more than the desired
number of recipients. The cells were kept on ice. Each dose was removed at the time of
injection, making sure not to flick the syringe and kill the cells and that there is no air in the
syringe.
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Adoptive Transfer by Tail Vein Injection
Recipient WT mice were given approximately 1-2 hours to rest after the irradiation. For the
adoptive transfer tail vein injection, (bone marrow transplantation), each mouse was dealt with
individually. The mouse is loaded into the restrainer slowly to ensure not to induce excessive
stress or cause shock. Once in the restrainer and it has been confirmed that the mouse has
enough room to breathe, apply Lidocaine gel to the tail (numbing agent and helps to make the
vessels more visible) and locate the most visible vessel. If available, a heat lamp can help to
help dilate the vessels. Pinch the tail directly over the chosen vessel to apply pressure prior to
the injection to again make the vessel more visible. These steps are especially important when
doing tail vein injections on darker colored mice. With a 25 gauge needle on a 1 mL syringe,
hold the bevel up, shallowly insert the needle into the vessel, and slowly inject the chimeric
suspension. If resistance is felt, the needle is not in the vessel and will need to be repositioned.
As soon the injection is completed, remove the mouse from the restrainer to reduce the chance
of shock and apply pressure to the injection site. Recipient mice were monitored for four weeks
to allow the transferred cells to reconstitute the irradiated immune system. Refer to Figure 3-2
for full timeline of the experiment.

Weigh and Monitor Daily

0

1

2

3

4

Weeks after injection

Figure 3-2: Mouse model of bone marrow chimera adoptive transfer
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Peritoneal and Splenic Lymphocyte Collection
After four weeks, the mice were euthanized. Lymphocytes were collected from the peritoneal
cavity by peritoneal lavage and from the spleen of each mouse. Peritoneal lavage was
conducted using 5 mL of sterile PBS. Lavage samples with visible blood in them could not be
used. Spleen samples were made into single cell suspensions using the Miltenyi gentleMACS
tissue dissociator and the majority of red blood cells were removed from the suspension using a
brief treatment with red blood cell lysis buffer.

Flow Cytometry
Lymphocytes were differentially stained for distinguishing markers. The general B cell marker
used was CD19 and was associated with the fluorophore APC. The general B-1 cell marker used
was CD43 and was associated with the fluorophore PE-Cy7. B-1a cells were distinguished from
B-1b cells using CD5, which is unique to B-1a cells and was associated with the fluorophore
FITC. Samples and FMOs were made to ensure gating would be accurate. Samples were
analyzed on FlowJo using the BD Biosciences LSRFortessa X-20 Cell Analyzer in the University of
Connecticut Flow Cytometry Facility.

RESULTS
Initial experiments showed very interesting results. When samples were taken from the
spleen and peritoneal cavity of WT and SCD mice, we saw the diminished B-1a cell population in
the spleen, consistent with the literature. More importantly though, we saw that B-1a cells are
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not diminished in the peritoneal cavity of SCD mice, (Figure 3-3), when compared to their WT
counterparts.

A

B

C

D

Figure 3-3: Flow Cytometry separating B cell subsets in the Spleen and Peritoneal Cavity – Naïve
B-1a cells of the spleen are diminished in SCD mice, but activated B-1 cells are still present in
the peritoneum. (A) WT spleen: B-1a cells present in WT spleen; (B) WT peritoneum: B-1a cells
present in WT peritoneum; (C) SCD spleen: B-1a cells diminished in SCD spleen; (D) SCD
peritoneum: B-1a cells present in SCD peritoneum. Gating strategy was stepwise, selecting the
lymphocyte population from the FSC vs SSC scatter plot and then sub-gating B cells off of that
using CD19-APC. Being displayed are CD43-PE-Cy7 vs CD5-FITC scatter plots. The double
positive (DP) gate denotes the B-1a cells. The CD43 gate denotes B-1b cells, which are CD43+
but CD5-. Lastly, the double negative (DN) gate denotes other, which includes the B-2 cells
because it was sub-gated off of the CD19+ population. All gating was based off of single stain
FMOs.
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B cells

A

60.3%

B cells

B

46.6%

CD19

CD19

B-2

B-1

B-2

40.1%

59.2%

43.5%

CD43
B-1b

47.5%

B-1a

52.2%

CD5

B-1

55.8%
CD43

B-1b

47.4%

B-1a

52.4%

CD5

Figure 3-4: B-1a cells show normal counts in the peritoneal cavities of SCD mice – (A) SCD and
(B) WT (control) mice. The percentages of B-1a cells in the peritoneal cavity of the SCD mice
were consistent with the range seen in the WT mice. Shown are plots from individual mice to
represent each group. For each flow plot, the following key applies:
[ ] Lymphocytes
[ ] B cells
[ ] B-1 cells

To test the feasibility of the hypothesis that the B-1a cells are diminished because their
developmental process has to occur in a hostile environment, a short experiment was
conducted to see how early the manifestations of SCD begin to be apparent. Histologic staining
was done on P0 mouse embryo organs that had been micro-dissected in RPMI media. The
spleen showed a potentially distinct phenotype (Figure 3-5). It appears that the SCD spleen
section is redder that the WT, leading to the speculation that sickled red blood cells may have
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already started to accumulate in the spleen at this time point. If this is the case, it could be
possible that the phenotypic changes associated with SCD occur early enough to affect
hematopoietic stem cell (HSC) development.

A

B

Figure 3-5: Neonatal (P0) Histology (hematoxylin and eosin stain) – (A) WT; (B) SCD: More blood
appears to be present in the spleen, but this representation is not able to show whether or not
the organization of the SCD spleen is still intact at the P0 stage.

Another way we went about answering the question of activation versus generation was
by studying the capacity of HSC’s in the adult bone marrow to form each B cell subset. Mixed
bone marrow chimera were formed from 9 parts congenic WT CD45.1 bone marrow to 1 part
SCD CD45.2 bone marrow from donor mice (same process for controls with 9 WT CD45.1: 1 WT
CD45.2; n=2). From there, the chimeras were adoptively transferred via tail vein injection into
WT CD45.2 recipients (n=3) who had been sub-lethally irradiated to ablate their bone marrow.
Once the recipients’ cells had been reconstituted, approximately 4 weeks post-transfer, splenic
cells were collected and stained for analysis by flow cytometry (CD19-APC, CD43-PE-Cy7, CD5FITC, CD45.1-PE). Analysis of the data showed that the transferred bone marrow chimera was
able to maintain the 9:1 ratio of WT CD45.1: SCD CD45.2 for each B cell subset (B-1a, B-1b, B-2)
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(Figure 3-6). The ratios were not exactly 9:1 but were within the bounds of error shown by the
control samples (± 4.8%). Peritoneal lavages using PBS were also done to collect the cells of the
peritoneum but the results were inconclusive and more tests will need to be done to clarify the
data.

A

86.5%
12.0%

B

90.8%
9.2%

CD45.1
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Figure 3-6: Analysis revealing consistent B cell ratios of SCD and WT cells in the spleen –
Histograms gated to show CD45.1+ and CD45.1– in each B cell subset of experimental and
control spleen samples. (A) Experimental: 9:1 (CD45.1:SCD) into WT – The progenitor cells from
the SCD bone marrow were able to maintain the 9:1 ratio for each cell subset as shown in the
flow cytometry plots. (B) Control: 9:1 (CD45.1:WT) into WT – The control’s ratios were within ±
4.8% of the 9:1 ratio of cells initially injected. The experimental data varied from an exact ratio
of 9:1, but the variation was within the confidence interval confirmed by the control. For each
flow plot, the following key applies:
[ ] B-1a cells
[ ] B-1b cells
[ ] B-2 cells
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DISCUSSION
From the experiments conducted in this paper, we are getting closer to figuring out the
cause/s and effect/s of the B-1a cell diminution in SCD. Looking at the B-1 cells’ pathway during
development, data showing that B-1a cells are diminished in the SCD spleen but not the SCD
peritoneum is very interesting. If the B-1 cells do indeed have to travel from the spleen to their
niche in the peritoneal cavity where they wait to encounter antigen, how can they be sent from
a diminished source and not be diminished in their final destination (Figure 3-3 & 3-4)? Is it
possible that a smaller number of cells are initially sent to the peritoneal cavity from the spleen
and then that set of cells divides to fill up the designated niche, making the B-1a cell population
a more monoclonal population? Or could it be that the appropriate cells are sent to the
peritoneal cavity before they are completely mature, leaving the cells in the peritoneal cavity
nonfunctional? To test the clonality of the B-1a cells in the peritoneum, we have started to
develop a protocol to prepare samples for BCR sequencing. We theorize that if the population
of B-1a cell population in the SCD peritoneum is more monoclonal that that of the WT, then the
B-1a cells populate the peritoneal cavity niche by expanding from a smaller set of starting cells.
If there is a set niche for the B-1a cells in the peritoneal cavity and a smaller number of cells are
sent from the spleen initially because the B-1a cells are diminished in the spleen, then when
they expand to fill the niche the cell population would be more monoclonal in nature. If the B1a cells of the SCD peritoneal cavity are polyclonal compared to the WT, then it is possible that
the cells bypass the spleen because of the disrupted architecture and go straight to the
peritoneal cavity? If the cells do not first go through the spleen, they are not able to become
activated and therefore would be nonfunctional in the peritoneal cavity (see Chapter 4). We are
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hoping to complete this BCR sequencing soon to be able to complete this story to an even
greater degree.
What is shown here about when SCD manifests itself in the spleen is just scratching the
surface (Figure 3-5). Different time points of these dissections and histologic staining should be
done to see when there begins to be a difference in the splenic architecture. In addition it may
be useful to look at different time points through immunohistochemical staining for each of the
immune cells that are supposed to be present in the spleen as was shown in Szczepanek’s 2012
publication, (3.7), to really get an idea for the starting point of the disrupted niche. By
discovering when the disease manifests itself in organs like the spleen, that time point can be
potentially correlated to a stage downstream in hematopoiesis. The B-1a progenitor cells can
then be studied at that time point to see if that is when the issue with their diminution begins.
From the results in Figure 3-6, which show that the 9:1 ratios were maintained by the SCD and
WT HSC’s within each B cells subset, we concluded that the HSC’s in SCD adult bone marrow
have the same capacity to proliferate and differentiate into each B cell subset as the HSC’s in
the WT adult bone marrow. This does not necessarily prove that there is not an innate issue
with the fetal stem cells that reside in the fetal liver and are responsible for the initial formation
of the B-1 cells, (0.1), but it does point towards the SCD B-1a diminution not being a result of an
innate issue with the stem cells capable of forming the B-1a cells. If the SCD HSCs are
completely capable of forming B-1a cells in a WT environment, what is stopping them from
completing the B-1a cell niche in the spleen in the SCD environment? Also, were the B cells
formed from the HSCs in the experiment displayed in Figure 3-6 functional? Future work will
need to continue to focus on identifying the mechanism by which B-1a cells become diminished
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in SCD mice in an effort to understand how this diminution effects the baseline immunity of
patients with SCD.
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CHAPTER 4

Publication in Review:
Peritoneal B-1b and B-2
B-cells Confer Long-term
Protection After
Vaccination with Prevnar13 and are Defective in
Sickle Cell Disease Mice
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ABSTRACT
Long-term immunity after pneumococcal conjugate vaccine (Prevnar-13) inoculation is impaired
in sickle cell disease (SCD) mice. We sought to determine which B-cell subsets confer long-term
immunity after Prevnar-13 vaccination in wild-type (WT) mice, but are defective in SCD mice.
We vaccinated donor WT and SCD mice three times at three week intervals with Prevnar-13.
Fourteen weeks later, 5*104 cells of isolated peritoneal B-1a, B-1b, and B-2 cells were harvested
from donors and intraperitoneally transferred to Rag -/- recipients. A week later recipients were
intraperitoneally challenged with 103 CFU of Streptococcus pneumoniae (serotype 3). Recipient
mice that received either B-1b or B-2 B-cells from WT mice survived challenge, whereas mice
that received B-1a cells died. Recipient mice that received B-1a, B-1b, or B-2 cells from SCD
mice died after challenge. Both B-1b and B-2 cells appear to confer long-term immunity after
Prevnar-13 vaccination, yet neither subset functions properly in SCD mice.

Keywords
Prevnar, PCV, Streptococcus pneumoniae, pneumococcal, B-cell, sickle cell
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INTRODUCTION
Sickle cell disease (SCD) is a hematological condition that ultimately impairs immunity and
leaves affected individuals susceptible to severe infections. The encapsulated bacterium,
Streptococcus pneumoniae (i.e. the pneumococcus), causes many of these infections and
invasive pneumococcal disease (IPD) has been found to be 10–100 times more prevalent in
children with SCD than the general population [4.1]. The induction of anti-pneumococcal
polysaccharide antibodies is the immunological correlate of protection for S. pneumoniae
vaccines, yet waning anti-pneumococcal antibody titers have been observed in children with
SCD after vaccination with the pneumococcal polysaccharide-conjugate vaccine Prevnar-13
[4.2, 4.3]. Furthermore, some pneumococcal isolates obtained from infected SCD patients in
the years since the licensure of Prevnar match serotypes found in the vaccine, indicating that
these individuals have insufficient post-vaccination immunity [4.4].
We previously characterized aberrant baseline immunity and dysregulated responses to a
model vaccine in transgenic SCD mice [4.5, 4.6], which led us to speculate about the efficacy of
clinically relevant vaccines in these mice. Using a prime-boost approach with Prevnar-13, we
showed that pneumococcal-specific IgG, IgG3, and IgM titers spike in vaccinated SCD mice
following inoculation but rapidly wane thereafter, even after booster shots are given.
Importantly, we also showed that these same mice are not protected when they are challenged
with a type-matched strain of S. pneumoniae three months after boosting, whereas control
mice are protected [4.7]. These data indicate that SCD mice lack long-term protective B-cell
responses after Prevnar-13 vaccination.
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Previous work in mice indicates that a subset of T-cell independent B-cells found in the
peritoneal cavity, called B-1a cells, are responsible for “natural immunity” against S.
pneumoniae infection, while the B-1b subset provides protection after vaccination with
pneumococcal polysaccharides. Conventional T-cell dependent B-2 cells have little contribution
to protective immunity in either of these cases [4.8]. The pneumococcal polysaccharideconjugate vaccine Prevnar was created such that T-cell dependent B-cell responses could be
induced in children under 2 years of age, as they do not have very strong T-cell independent Bcell responses. Unfortunately, no one has previously identified which B-cell subset(s) responds
to Prevnar in mice. We sought to better understand this basic question so that we could
identify which B-cell subset(s) is dysfunctional and prevents long-term immunity after Prevnar13 vaccination in SCD mice.

METHODS
Mice. Donor mice were two to three month-old male and female mice harboring knock-ins of
the human alpha globin transgene, along with either a normal human beta globin or sickle beta
globin transgene [B6;129-Hbatm1(HBA)Tow Hbbtm2(HBG1,HBB*)Tow/Hbbtm3(HBG1,HBB)Tow /J; Jackson Labs
stock number 013071] [4.9]. Mice homozygous for the normal human beta globin transgene are
henceforth referred to as “wild-type” (WT) mice and those homozygous for the sickle beta
globin transgene are referred to as SCD mice. Recipient mice were two to three month-old male
and female mice homozygous for a knockout of the Rag 1 gene (Rag -/-) [B6.129S7Rag1tm1Mom/J; Jackson Labs stock number 002216]. These mice were selected from a colony
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that we maintain at the University of Connecticut, using IACUC approved methods (protocol #
A14-029).
Vaccination. Donor mice were vaccinated as previously described [4.7]. Mice were rested for 14
weeks after the second boost was administered, then they were humanely euthanized by CO 2
overdose immediately prior to peritoneal lavage.
B-cell harvesting, subset selection, and adoptive transfer. Peritoneal leukocytes were
harvested via lavage. After washing and resuspension, cells were counted using a
hemocytometer and Trypan Blue dye. 4*107 cells were then mixed with a cocktail of antiNKp46-Biotin and B-1a cell biotin antibodies (which includes anti-CD5/APC antibodies) at 1:4
dilutions in MACS buffer, allowed to incubate for 10 minutes with anti-biotin microbeads, and
then run over a magnetic LD column to deplete non-B-cells (Miltenyi Biotec, Cambridge, MA).
B-1a cells were then positively selected using anti-APC microbeads at a 1:4 dilution and a MS
column. The flow-through from the previous step was then mixed with CD43 microbeads at a
1:90 dilution in MACS buffer and run over a MS column to positively select for B-1b cells. B-2
cells remained in the flow-through from the previous step. Preparations were approximately
80-95% pure, as determined by flow cytometry. After selection, cells were washed and
resuspended in B-cell transfer buffer [citation (Zuccarino-Catania)], and 5-6*104 cells were
intraperitoneally transferred to Rag -/- recipient mice (controls included mice sham-transferred
with transfer buffer alone). After adoptive transfers were completed, live cell counts were
conducted on the stocks to ensure recipient mice received the appropriate concentration of live
cells.

58

Bacteria and infection. The A66.1 Streptococcus pneumoniae strain, which expresses
pneumococcal polysaccharide serotype 3 (PPS3), was slowly thawed from -80oC, diluted in
Todd-Hewitt broth and kept on ice. Mice were intraperitoneally infected one week after cell
transfer with 1*103, 1*104, or 1*105 CFU of bacteria in 200ml of Todd Hewitt broth (or shaminfected with broth alone as a control). After infections were completed, stock bacterial
solutions were grown overnight on blood agar plates to ensure that infected mice received the
appropriate dose of live bacteria. Infected mice were monitored for signs of distress or illness,
and mortality was recorded.
Statistics. Mortality curves were assessed for statistical differences using the log-rank/MantelCox test. Significance was determined using p < 0.05 as a cutoff. Statistics were calculated using
Prism version 6 software (GraphPad, La Jolla, CA).

RESULTS
Peritoneal B-1b and B-2 cells confer long-term protection from pneumococcal infection after
Prevnar-13 vaccination, both of which are defective in SCD mice
All Rag -/- recipient mice that were challenged with 1*104 or 1*105 CFU succumbed to infection
by day 2 post-infection, regardless of group. All recipient mice that received a sham-transfer of
cells and were challenged with 1*103 CFU of bacteria died by day 2 post-infection, whereas
those that were sham-transferred and sham-challenged lived for the 10 day duration of the
study. All recipient mice that received either B-1b or B-2 B-cells from WT mice survived 1*103
CFU challenge, whereas all mice that received B-1a cells from WT mice died by day 2 post59

infection. All recipient mice that received B-1a, B-1b, or B-2 cells from SCD mice died from
infection with 1*103 CFU of the bacteria (Figure 4-1). In order to determine if B-1a cells from
WT donor mice have a relative defect in protecting recipient mice from pneumococcal infection
(when compared to B-1b and B-2 B-cells), we transferred 2.5*105 B-1a cells to Rag -/- recipients
(5 times more cells than other recipients) and intraperitoneally challenged them with 1*10 3
CFU of bacteria, with the same control groups described above. These mice still succumbed to
pneumococcal infection (data not shown), indicating that B-1a cells are not involved in longterm protection after Prevnar-13 vaccination.

DISCUSSION
The cellular correlates of protection have been well elucidated in mice for pneumococcal
polysaccharide vaccines, which seems to rely heavily on peritoneal B-1b cells in both young and
aged mice [4.8, 4.10]. Unfortunately, this vaccine suffers from weak immunity in both very
young and elderly people, as well as many groups with various chronic diseases. The
development of Prevnar has helped to resolve many of the problems associated with
immunization with plain polysaccharide vaccines. This is presumably accomplished through the
addition of T-cell help, which should expand the repertoire of responding B-cells (to include
conventional B-2 cells), but this has never been explicitly shown in mice. In this work we found
that this presumption is indeed true, as peritoneal B-2 cells from Prevnar-13 vaccinated WT
donor mice (14 weeks after boosting) were capable of conferring protection from
pneumococcal infection in Rag -/- recipient mice. Interestingly, we also found that B-1b cells are
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capable of protecting recipient mice from infection, indicating that this vaccine can stimulate Bcells in both a T-dependent and T-independent manner. B-1a cells from Prevnar-13 vaccinated
WT donor mice were not capable of conferring long-term protection from infection, even when
5 times more cells are transferred to recipient mice.
While Prevnar has been shown to overcome immune deficiencies in many groups with chronic
conditions, efficacy is not always equivalent between these groups and the general population,
or between transgenic mice and WT littermates. The lack of long-term protection from
infection after multiple inoculations with Prevnar-13 in SCD mice is concerning, as it indicates
that there is a lack of development of both B-cell memory and long-lived plasma cells when
these mice are vaccinated. Our current finding that neither B-1b nor B-2 cells from vaccinated
SCD donor mice can protect Rag -/- recipient mice from pneumococcal challenge (whereas
these same cells from WT donors do) helps to enlighten us as to why the long-term efficacy of
Prevnar-13 is so poor in SCD mice. Understanding what gene pathways are aberrant in these
cells throughout the vaccination model will provide insight as to the potential molecular
mechanism(s) that is responsible for dysfunctional immunity to Prevnar-13. Future research
should also focus on understanding the functionality of “equivalent” cells in SCD patients,
namely CD19+CD20+CD27+IgM+CD43+CD5+/- B-cells [4.11, 4.12].
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Figure 4-1. B-1b and B-2 cells, but not B-1a cells, confer protection in WT mice after
vaccination with Prevnar-13, but are defective in SCD mice.
WT and SCD donor mice were vaccinated three times with Prevnar-13. B-cells were harvested
from the peritoneum, subsets were selected using magnetic beads, and 5-6*104 cells from each
subset were transferred to Rag -/- recipient mice. Recipient mice were intraperitoneally
challenged with 1X103 CFU of A66.1 and mortality was assessed. p = 0.01 for all three datasets,
as determined by the log-rank/Mantel-Cox test.
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Discussion and
Conclusions
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The significance of the research conducted on the immune capacity in SCD is much
greater than just obtaining the results. Patients, especially children, who are suffering from SCD
not only have to deal with the direct manifestations of the sickled red blood cells circulating
throughout their body, but they also have to be careful about infections as they are highly
susceptible. With the results that are being obtained, a story will eventually come together to
explain why there is a decreased immune capacity associated with SCD and potentially how to
treat it so that patients can lead more normal lives. Here I have conducted research in different
disciplines that I can apply to SCD. Szczepanek showed that B-1a cells are diminished in the
spleens of SCD transgenic mice. I became interested in this cell type, wondering at what point
in its development it is affected by the disease. The B-1a cells have been shown to specifically
help to mount a response against S. pneumoniae infection so it made sense to look at these
cells as a potential factor in the increased susceptibility to infection by this specific bacteria. I
was recruited to help complete experimentation for the publication included as Appendix,
where we concluded that the poor long-term efficacy of Prevnar-13 in SCD mice is associated
with an inability to sustain pneumococcal polysaccharide-specific antibody titers. We predict
that this may be correlated to the lack of long-lived plasma cell generation in the SCD mice and
a lacking B cell memory from the vaccine, even after boosting. So in addition to the decreased
baseline immunity in SCD, there is decreased efficacy of the vaccine that is meant to help
protect against of the main bacteria that infects patients with SCD. If normal protection against
S. pneumoniae is facilitated by the B-1a cells, we thought it may be possible that Prevnar-13
acted through this cell type as well, as it did not work in the disease model of SCD where the B1a cells are diminished.
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With this background about SCD, B-1a cells, Prevnar-13, and S. pneumoniae we decided
to formulate a few different angles to look at this topic. I wanted to take a look at the
interactions between the different body systems as they develop to see if there were any other
factors that could be affecting the B-1a cells. First I looked at hematopoiesis and how SCD may
affect it (Chapter 1). Congestion of the circulatory system occurs in SCD and could cause issues
with trafficking of cells as well as signaling molecules. HSCs niches have a specific environment
that keeps the HSCs pluripotent. If the niche for these cells in the bone marrow or the fetal liver
or a niche for a more specific immune stem cell in the spleen is disrupted, as it may be due to
the circulation of injurious sickled cells or the lack of proper architecture in the SCD spleen,
then the microenvironment needed by the stem cells for proper maintenance, activation, and
differentiation could disappear entirely. Once component of the normal circulatory system that
is drastically different in the HSC niche is the level of oxygen. If the HSC’s use this oxygen
gradient as a sort of signaling to know when to become activated, then in SCD where there is
much less circulating oxygen this signaling could also be disrupted and HSC source could
become compromised. In both of these possible cases, a common issue that could be occurring
is cell exhaustion. If the HSCs are activated for too long or by too many different signals then
maybe they lose some of their functioning capacity. That same idea could apply to
differentiated immune cells as well. Maybe they are too busy trying to clear the body of
hemolytic particulates and apoptotic debris that their sensitivity to invading pathogens like S.
pneumoniae is decreased. These ideas would interesting to investigate in the future.
The other mayor developmental process I wanted to look into with the premise of
comparing it to the stressful environment of SCD was the neuroendocrine system (Chapter 2).
67

The bidirectional communication between the neuroendocrine system and the immune system
during development was particularly appealing because of the effect of stress on each of the
systems. Stress in SCD is causes by things like vaso-occlusion, anemia, increased hemolysis, and
splenomegaly. In addition, a Zn deficiency has been found which increases the levels of stress
even (supplementation decreases oxidative stress, infection incidence, and generation of
inflammatory cytokines). In addition it causes decreased immunity, lymphopenia in the bone
marrow, and increased glucocorticoid production. I discovered that under stressful conditions,
glucocorticoids actually become immunosuppressive by increasing apoptosis and decreasing
lymphopoiesis, especially in the B cell compartments. With the levels of stress associated with
SCD, glucocorticoids that are produced would most likely take on this role. In addition to stress
related immunity, there could also be a correlation between signaling and the circulatory
congestion in SCD. Is it possible that hormone levels and/or their signaling pathways are
affected by this, disallowing crucial signaling molecules to stimulate processes like lymphoid
hematopoiesis, movement, and proliferation? Generally the body is working properly if
homeostasis is maintained so if certain sources are being blocked then imbalances could arise
and cause improper signaling. Also, supplementation hormones from a mother’s milk could be
enough to maintain the necessary immunostimulatory signals to counterbalance the
immunosuppressive signals that are caused by the disease.
After familiarizing myself with the field and learning about the many things that could
be affecting the immune system in SCD, I was able to formulate and conduct my own
experiments to try and discern the causes and effects of the decreased baseline immunity in
SCD (Chapter 3 & 4). We saw that HSCs from the adult bone marrow in SCD and WT have equal
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capacity to form each of the B cell subsets in the spleen. With these results we have evidence
that the diminution is not an innate issue with the adult stem cells. Further experimentation
should be done using fetal stem cells to see if the results are consistent. But if there are fewer
B-1a cells in the SCD spleen then why are the fully capable HSCs not producing more cells? To
gain more evidence that the B-1a cell diminution of SCD is not an issue of generation, the
induction of HSCs/FSCs and how they development into B-1 cells must be studied in depth.
In terms of the peritoneal cavity, we found that even though B-1a cells are diminished in
the SCD spleen, their numbers in the peritoneal cavity are unchanged from those of WT (see
Chapter 3, Discussion). One of our hypotheses about the B-1a cells in the SCD peritoneal cavity
is that a small group of seeding cells are initially sent from the smaller group of cells in the
spleen and then when the cells reach the peritoneal cavity, their niche is undisrupted,
potentially unlike their niche in the spleen, so they proliferate to fill up the niche. If this were
the case then the B-1a cell population in the peritoneal cavity of SCD mice would be a more
monoclonal population in terms of their VDJ combinations, which we are currently testing using
BCR sequencing. Our other hypothesis is that the cells that end up in the peritoneal cavity
bypass the spleen entirely because of the improper architecture. Because the cells need the
spleen to become activated, this explanation would render the cells nonfunctional in the
peritoneal cavity. This hypothesis was tested by the experimentation in Chapter 4.
With the method that was used to test the functionality of the peritoneal B cells, we
were unable to see if the B-1a cells were more or less functional in the SCD than the WT
because neither the SCD nor the WT vaccinated donor B-1a cells conferred protection from S.
pneumoniae infection. In fact, none of the B cell subsets from the vaccinated SCD donor mice
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were able to confer protection from infection with S. pneumoniae in Rag -/- mice. So, even
though the B cells number in the peritoneal cavity of SCD mice appear normal, the cells are not
functional in conferring protection from infection after vaccination. This could be a reason why
SCD mice lack long-term protection from infection after Prevnar-13 vaccination (Appendix). If
those cells are nonfunctional in the peritoneal cavity, there is a good chance that they are also
unable to form a memory of the pathogen. Although we were not able to learn much about the
functionality of the peritoneal B-1a cells in SCD from this experiment, we were able to learn
more about Prevnar-13. Until now, it was unknown which of the B cell subsets responds to
Prevnar-13 vaccination. The vaccine was presumed to work through T cell help which we were
able to show because the WT peritoneal B-2 cell transfers were able to confer protection from
S. pneumoniae infection in Rag -/- recipient mice. The B-1b cells from the vaccinated donor
mice were also capable of protecting against infection, meaning this vaccine works in both a T
cell dependent and independent manner. So even though the B-1a cells are thought to be
important in mounting a response against S. pneumoniae infection, they are seemingly not
recruited in response to Prevnar-13 vaccination in WT or SCD mice. The mechanism of this
vaccine in the WT and SCD model needs to be studied in more depth.
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Abstract
Background
One of the most common causes of morbidity and mortality in children with sickle cell disease (SCD) is infection with the pneumococcal bacterium (Streptococcus pneumoniae).
Unfortunately, the polysaccharide-conjugate vaccine appears to be less effective in individuals with SCD when compared to the general population. We sought to better understand
the relative efficacy of pneumococcal vaccination in a SCD mouse challenge model.

Methods
Transgenic control and SCD mice were monitored for mortality after intranasal pneumococcal infection or pneumococcal vaccination with Prevnar-13 and type-matched challenge.
Anti-pneumococcal antibody titers were measured by ELISA and opsonophagocytosis was
measured in vitro.

Results
Mortality after pneumococcal infection was similar between control and SCD mice. However, after three intramuscular polysaccharide-conjugate vaccinations, all control mice
were protected following high-dose intranasal infection, whereas 60% of SCD mice died.
Anti-pneumococcal antibody titers showed initial IgG and IgM responses in both groups, but
waning titers were observed in the SCD group, even after boosting. When functionally
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assayed in vitro, serum from SCD mice 13 weeks after a second booster shot maintained little to no ability to opsonize pneumococci, while serum from control mice sustained a significantly higher capacity opsonization. Thus, it appears that SCD mice do not maintain
antibody responses to pneumococcal polysaccharides after Prevnar-13 vaccination,
thereby leaving them susceptible to mortality after type-matched infection.

Conclusion
Our results emphasize the need to better understand the correlates of immune protection in
SCD so that pneumococcal vaccines can be improved and mortality reduced in this susceptible population.

Introduction
Sickle cell disease (SCD) is a complex hematological disorder that has a dramatic effect on
immunity and resistance to infection. The current case-fatality rate within this population due
to infection (when not adjusted for age) stands at approximately 14% [1]. Children with SCD
are at a particularly high risk for infection with the encapsulated bacterium, Streptococcus
pneumoniae (i.e. pneumococcus), which is presumably due to altered splenic architecture and
function [2]. A life-threatening condition arises if the bacterium becomes invasive and causes
bacteremia (known as invasive pneumococcal disease, or IPD). IPD has been found to be 10–
100 times more prevalent in children with SCD than the general population [3] and is even
twice as likely in individuals with sickle cell trait [4, 5]. Given the extreme morbidity and mortality associated with pneumococcal infection in the SCD population, current clinical guidelines dictate that these patients be placed on prophylactic penicillin at approximately 4 months
of age and adhere to a strict regimen of pneumococcal vaccination.
Cases of splenectomy have demonstrated that the spleen is a crucially important organ in
protection from IPD in both humans [6] and mouse models [7]. Previous vaccination appears
to be sufficient to maintain antibody titers in many cases of splenectomy; however, retention of
memory B-cells is adversely affected [8]. Furthermore, while it is agreed upon by most in the
field that anti-pneumococcal titers are induced in children with SCD shortly after vaccination,
it has been reported that titers may not be maintained long-term after vaccination with the unconjugated pneumococcal polysaccharide vaccine [9], indicating that these children may have
defects in the generation of memory B-cells and/or long-lived plasma cells. Protection from
IPD has been demonstrated to rely heavily on the presence of “memory IgM B-cells” (human)
or “B-1a B-cells” (mouse) [10, 11]. These cells produce antibodies that target carbohydrate
moieties commonly found on encapsulated bacteria. The presence of a functional spleen has
been shown to be essential to the survival of these cells [12]. Interestingly, we have previously
shown that splenic architecture is disrupted in transgenic SCD mice and B-1a B-cells are dramatically reduced in number in the spleens of these mice [13]. Hence, it is likely that the generation of a robust plasma cell and memory B-cell response is essential to thwart recurrent
pneumococcal infection, and a lack thereof may be responsible for increased susceptibility in
children with SCD who lack splenic function and normal numbers of memory IgM B-cells.
Since the introduction of the use of prophylactic penicillin and the newer pneumococcal
polysaccharide-protein conjugate vaccine Prevnar in children with SCD, hospitalization associated with infection from this pathogen has been reduced three-fold [14] and infection has been
concomitantly reduced to approximately one-third of its previous level [15]. Unfortunately,
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this still leaves room for improvement in treatment and therapies to combat infection by this
pathogen in children with SCD. Given the strict adherence to pneumococcal vaccination in
SCD patients at many hematology clinics, this phenomenon is surprising and vaccine failure
may be to blame for some of these cases. While little is known about the ability of Prevnar to
specifically protect from type-matched infection in SCD patients, we do know that the
23-valent pneumococcal polysaccharide vaccine has been shown to have little to no efficacy in
SCD patients in some reports, even after administering a booster dose [16, 17]. Hence, the efficacy of pneumococcal vaccination does not appear to be as high in children with SCD when
compared to the general population.
Immune dysregulation in the transgenic SCD mouse model has recently become apparent.
We have shown that disrupted splenic architecture is prevalent at a young age in these mice, as
are aberrations in the distribution of lymphocyte populations, cytokines/chemokines, and antibody classes [13]. Further changes in immunity have been noted after animals received a vaccination with ovalbumin and the adjuvant aluminum hydroxide (OVA/alum). These
vaccinations resulted in high IgE titers, further dysregulation of cytokines/chemokines/antibodies, and a notable increase in the levels of IL-1β and IL-6 in bronchoalveolar lavage fluid of
the SCD mice [18]. Given our previous findings that immunity is dysregulated in the SCD
mouse model, we hypothesize that immunity is impaired in SCD and drives the reduced pneumococcal vaccine efficacy that has been clinically observed in this population. Herein we
describe the immunogenicity and efficacy of the pneumococcal polysaccharide-conjugate vaccine Prevnar-13 in the SCD mouse model to address the above hypothesis.

Materials and Methods
Animal Research Ethics Statement
This study was carried out in strict accordance with the recommendations in the Guide for the
Care and Use of Laboratory Animals of the National Institutes of Health. The protocol was
approved by the Institutional Animal Care and Use Committee at Albany Medical College
(protocol #14–04003; Metzger) and the University of Connecticut (protocol #A14-029; Szczepanek). During experimental infections, mice were weighed daily and checked for signs of distress. Mice that were determined to exhibit moderate to severe clinical signs (i.e. severely
reduced mobility or persistent recumbency) were considered for euthanasia via an overdose of
the anesthetic sodium pentobarbital followed by cervical dislocation (conducted by staff
trained in the use of the technique).

Mice
Two to three month-old female mice harboring knock-ins of the human alpha globin transgene, along with either a normal human beta globin or sickle beta globin transgene [B6;129Hbatm1(HBA)Tow Hbbtm2(HBG1,HBB )Tow/Hbbtm3(HBG1,HBB)Tow/J; stock number 013071] were purchased from Jackson Laboratories (Bar Harbor, ME). Mice homozygous for the normal human
beta globin transgene are henceforth referred to as “control” mice and those homozygous for
the sickle beta globin transgene are referred to as SCD mice. Serum for ELISA was obtained via
retro-orbital bleed. Five to eight mice were used for all experiments. All mice were maintained
and utilized at the Albany Medical College Animal Facility.

Bacteria
The A66.1 S. pneumoniae strain, which expresses pneumococcal polysaccharide serotype 3
(PPS3), was cultured at 37°C in Todd-Hewitt broth until mid-log phase (using BSL-2
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precautions), washed and resuspended in fresh broth containing 15% glycerol, and stored at
−70°C until use.

Infection
Infection was induced in naïve, unvaccinated mice intraparitoneally anesthetized with ketamine HCl (Fort Dodge Animal Health, Fort Dodge, IA) and xylazine (Phoenix Scientific,
St. Joseph, MO) in PBS and inoculated intranasally with a dose of 5 X104 CFU of A66.1 pneumococci in 50 μl of Ringer's solution. Mice were weighed daily, monitored for signs of distress
or illness, and mortality was recorded. Lungs were removed from mice that died during infection and were fixed overnight in 10% formalin, embedded in paraffin and sectioned, and H+E
stained using standard protocols of the CT Veterinary Medical Diagnostic Laboratory
(CVMDL) at the University of Connecticut. Resolution of S. pneumoniae in the lungs was performed using a Gram stain of paraffin-embedded tissues. Histologic evaluation of lung lesions
was conducted by a board-certified veterinary pathologist from the CVMDL.

Vaccination and Challenge
Mice were intramuscularly inoculated in the hindlimbs with Prevnar-13 (Wyeth Pharmaceuticals, Collegeville, PA) with a dose containing 0.22 μg of each polysaccharide. This vaccine
includes PPS3. The mice were boosted twice, tested for serum anti-PPS3 antibodies, and challenged according to the schedule outlined in Fig 1. Challenge of vaccinated mice was conducted
via intranasal inoculation of 1X106 CFU of A66.1 pneumococci in 50 μl of Ringer’s solution.
Mice were weighed, monitored for signs of distress or illness, and mortality was recorded.

ELISA
PPS3-specific antibody titers were measured using ELISA. 96 well Polysorp Nunc-Immuno
plates (Nalge Nunc International, Rochester, NY) were coated with 50 μL of PPS3 antigen
(2 μg/mL, ATCC, Manassas, VA) and incubated at 4°C overnight. Plates were then washed
three times with PBS (Life Technologies, Carlsbad, CA) containing 0.05% Tween 20 (Sigma)
and then blocked with 5% fetal calf serum (Hyclone Laboratories, Inc., Logan, UT) at room
temperature for 1 hr. Serial dilutions of serum in blocking buffer were added to the plates,
which were then incubated at room temperature for 2 hr. After five washes with PBS-0.05%
Tween20, 50 μL of biotin-conjugated goat anti-mouse IgG or IgM antibody (SouthernBiotech,
Birmingham, AL) was added, and the plates were incubated at room temperature for 1 hr.
After six washes, 50 μL of Streptavidin-HRP (Biosource/Life Technologies, Carlsbad, CA) was

Fig 1. Mouse model of pneumococcal vaccination and infectious challenge. 2–3 month old mice were
bled, and serum was collected prior to initial priming with Prevnar-13 on week 0. Mice were boosted on weeks
3 and 5 with the same vaccine. Mice were again bled on weeks 4, 9, and 14. Mice were then challenged with
the virulent A66.1 strain of S. pneumoniae on week 18 and mortality was assessed for 16 days after
challenge.
doi:10.1371/journal.pone.0149261.g001
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added and the plates were incubated at room temperature for 30 mins. After seven washes,
50 μL of TMB Peroxidase substrate solution was added. 50 μl of 1.8 N Sulfuric acid was used to
stop the reaction. Finally, the absorbance was measured at 450 nm using a microplate reader
(BioTek Instruments, Inc., Winooski, VT). Dilutions corresponding to 50% maximal binding
were used to calculate serum titers.

Opsonophagocytic Killing Assay
The protocol used is adapted from Romero-Steiner et al. [19]. Mouse macrophage J774a.1 cells
obtained from ATCC (Manassas, VA) were thawed and cultured according to manufacturer
recommendations. J774a.1 cells were then added to 96-well round bottom plates at a concentration of 4 x104 cells/well and incubated with a pneumococcal cells (A66.1) at a concentration
of 2 x 105cells/well, diluted from a stock of a known concentration (using CFU counts on blood
agar plates). Serum was collected from Prevnar-13 vaccinated control and SCD mice 13 weeks
after their third vaccination, which was then diluted 1:2 in assay buffer. Mouse complement
(Rockland Antibodies and Assays, Limerick, PA) was added at 10 μl/well (890 μg). Following
final incubation, a 10 μl aliquot was diluted 1:10 in Todd-Hewitt Broth and 20 μl was plated on
to blood agar plates and incubated for 18 hr at 37°C. Colonies were counted and compared to a
no serum control. Data are expressed as the percentage of phagocytosis over no serum control.

Statistics
Mortality curves were assessed for statistical differences using the log-rank/Mantel-Cox test.
Statistical differences in body weight over time were determined using repeated-measures
ANOVA. Differences in antibody titers were determined separately at each time-point for
between group comparisons using a two-tailed t-test, while within group comparisons across
time points were determined by One-way ANOVA. Opsonophagocytosis between groups was
compared using a two-tailed t-test. Significance was determined as p < 0.05. Statistics were calculated using Prism version 6 software (GraphPad, La Jolla, CA).

Results
Mortality and Histopathology After Pneumococcal Infection
Initial pilot studies with non-transgenic wild-type mice of the same genetic background as the
SCD mice identified 5X104 CFU as the approximate LD50 for intranasal A66.1 pneumococcal
infection (data not shown) and this dose was subsequently used in the SCD mouse model.
Overall mortality after eight days of infection was not different in both SCD (n = 8) and control
mice (n = 8). Although SCD mice tended to die earlier than control mice (Fig 2a), there was no
statistical difference in the mortality curves between the two groups. Similarly, there was no
statistical difference between the groups in weight lost after infection (Fig 2b).
In this study, lungs from infected control mice (Fig 3a) were much more severely inflamed
than those from SCD mice (Fig 3b), with notable perivascular and peribronchial infiltrates and
pleuritis in the control mice that was very mild to absent in SCD mice. Pneumococcal bacteria
were visually present in both the blood and attached to the surface of the lung tissue in the control mice (Fig 3c), whereas they were only observed in the blood of SCD mice (Fig 3d). Thus,
lung colonization was associated with lung lesions in control mice that died from infection, but
mild lung lesions were associated with the visual presence of the bacteria only in the blood of
SCD mice that died from infection.
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Fig 2. Differential mortality kinetics of control and SCD mice after infection. 2–3 month old mice were infected intranasally with 5X104 CFU of A66.1 S.
pneumoniae and mortality (A) and weight loss (B) were measured. No statistical differences were observed for either parameter. White boxes = SCD, black
boxes = controls.
doi:10.1371/journal.pone.0149261.g002

Fig 3. Histopathology and Gram staining of lung tissues in mice that succumb to intranasal pneumococcal infection. H+E staining of lung tissue
from control (A) and SCD (B) mice after they succumbed to pneumococcal infection. Gram stain of the same lung tissue in control (C) and SCD (D) mice.
Wide arrows point to pneumococci in blood vessels and narrow arrows point to pneumococci colonizing the surface of the lung tissue.
doi:10.1371/journal.pone.0149261.g003
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Antigen-specific Antibody Titers and Functional in vitro
Opsonophagocytosis of Pneumococci After Vaccination with Prevnar-13
After intramuscular priming and boosting with Prevnar-13 (as indicated in Fig 1), serum antiPPS3 total IgG, IgG3, and IgM antibody titers were measured by ELISA. Initial anti-PPS3 total
IgG and IgG3 titers increased within 4 weeks in both control (n = 5) and SCD (n = 5) mice (Fig
4), which is in keeping with clinical findings of induced antigen-specific titers shortly after vaccination in people with SCD. These titers continued to significantly increase (p < 0.05) in the
control animals after booster shots were administered, as was expected. Conversely, anti-PPS3
total IgG and IgG3 titers significantly waned to near naïve levels in SCD mice at the 9 and 14
week time points, even with repeated boosting (p < 0.05). Not surprisingly then, the anti-PPS3
total IgG and IgG3 titers were significantly higher in control mice when compared to SCD
mice at the 9 and 14 week time points (p < 0.01 and p < 0.05, respectively). Control mice
trended towards an increasing anti-PPS3 IgM response (p = 0.08) over time, whereas SCD
mice induced a strong initial anti-PPS3 IgM response (week 4) that again waned to near naïve
levels thereafter (p < 0.05). These findings are in line with clinical observations that anti-pneumococcal antibody titers are not maintained long-term in people with SCD.
Functional analysis of the long-term antibodies that are induced by three shots of Prevnar13 were determined using an in vitro opsonophagocytic killing assay (Fig 5). Exogenous mouse
complement was added to the assay to ensure that differences between groups for macrophages
to phagocytose pneumococci were the result of differences in antibody titer and/or quality, and
not due to differences in complement. Serum from control mice (n = 3) maintained a significantly higher (p < 0.05; mean = 64% over no serum control) ability to opsonize pneumococci
than serum from SCD mice (n = 3, mean = 35% over no serum control) 13 weeks after a third
shot with Prevnar-13. Notably, pooled serum from unvaccinated control and SCD mice was
not much different in its capacity to opsonize pneumococci (mean = 32 and 26, respectively)
than vaccinated SCD mice. These findings are in line with the nearly naïve anti-PPS3 titers
observed in SCD mice after three injections with Prevnar-13 and indicate that the waning antigen-specific titers observed in SCD mice are functionally relevant.

Mortality from Infectious Challenge After Vaccination with Prevnar-13
We used a challenge dose of A66.1 that is approximately two orders of magnitude higher than
the LD50 dose in unvaccinated mice to ensure that observed survival is associated with vaccination. Mice were intranasally given 1X106 CFU of A66.1 pneumococci (PPS3, a serotype found
in Prevnar-13) approximately three months after the last vaccine boost was administered. All
control mice (n = 8) survived challenge with virulent PPS3; however, 60% of SCD mice (n = 5)
died after infection (Fig 6, p = 0.01). Hence, the vaccine appears to have little long-term efficacy
in the SCD mouse model, which correlates with the waning antibody titers observed in these
animals at the time of challenge.

Discussion
The importance of pneumococcal vaccination in children with SCD cannot be overemphasized
due to the devastatingly high morbidity and mortality associated with infection by this pathogen. While the pneumococcal polysaccharide-protein conjugate vaccine Prevnar has dramatically reduced infectious burden in children with SCD, far too many cases of pneumococcal
infection still occur every year in this group and little is known as to why this is the case. We
found in our infection model that mortality for both control and SCD mice were similar, which
was surprising given the dramatically increased vulnerability of children with SCD to
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Fig 4. Pneumococcal-specific antibody titers after vaccination. PPS3-specific total IgG (A), IgG3 (B),
and IgM (C) antibody titers were measured by ELISA in Prevnar-13 vaccinated 2–3 month old control and
SCD mice at weeks 0 (before vaccination), 4, 9, and 14. * = p < 0.05 and ** = p <0.01 for between groups
comparisons at the same time point (as determined using a two-tailed Student’s T-test) and † = p < 0.05 for
within group comparisons across time points (as determined using a One-way ANOVA). For IgM
comparisons between groups, p = 0.07 and p = 0.08 at weeks 4 and 9, respectively. For IgM comparisons
within the control group, p = 0.08. White boxes = SCD, black boxes = controls.
doi:10.1371/journal.pone.0149261.g004
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Fig 5. in vitro opsonophagocytosis of pneumococci 13 weeks after boosting with Prevnar-13. Serum
from vaccinated mice (or pooled serum from naïve mice) was mixed with exogenous mouse complement and
A66.1 S. pneumoniae and added to cultures of mouse macrophages in vitro. Mixtures were then streaked out
on blood-agar plates, incubated at 37°C overnight and viable pneumococcal colonies were counted. Data are
reported as the percentage of pneumococcal colonies that were not phagocytosed by macrophages when
compared to “no serum control” wells. p < 0.05 as determined by a t-test. Comparisons to naïve mice were
not performed as those samples were pooled.
doi:10.1371/journal.pone.0149261.g005

pneumococcal infection. Furthermore, Miller et al. previously reported that SCD mice are
hyper-susceptible to pneumococcal infection [20]. However, this study followed mice for a
much shorter duration (72 hours), and our results agree with their findings up to this time
point as we observed a delay in mortality in the control mice when compared to SCD mice

Fig 6. Prevnar-13 vaccination does not protect SCD mice from pneumococcal infection. Mice were
vaccinated and challenged according to the schedule outlined in Fig 1. Mice were intranasally challenged
with 1X106 CFU of A66.1 and mortality was assessed measured. p = 0.01, as determined by the log-rank/
Mantel-Cox test. White boxes = SCD, black boxes = controls.
doi:10.1371/journal.pone.0149261.g006
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early in infection. Interestingly, SCD mice that died from pneumococcal infection had mostly
mild lung lesions, and pneumococci could only be found in the blood when tissues were Gram
stained. This was in contrast to control mice that died from infection, which exhibited moderate to severe lung lesions and pneumococci could be observed in both the blood and along the
surface of the lung tissue. While requiring further investigation before any definitive conclusion can be reached, given the relative delay in the time to death in control mice and the relative
lack of lung lesions/colonization in SCD mice, it appears that SCD mice may experience IPD
earlier in infection and do not require lung colonization for this to occur, whereas control mice
do. Such an explanation would be in line with the in vivo bioimaging data presented by Miller
et al. [20], which showed that pneumococci remain in the lungs of WT mice 24 hours after
infection, but IPD occurs within this same time period in SCD mice.
Given our finding of the overall lack of a difference between the groups in terms of susceptibility infection, we were further surprised when the SCD mice differentially succumbed to
infectious challenge after vaccination. It is important to note that the challenge dose after vaccination that we used is two logs higher than the dose used during the infection study (which
killed more than half of the mice in both groups). Thus, mice would likely require a protective
immune response to be induced from vaccination in order to survive this high challenge dose,
and protective antibody responses were only maintained in the control mice at the time of challenge. These findings correlated with an in vitro opsonophagocytic killing assay conducted
using serum from control and SCD mice 13 weeks after their second booster shot with Prevnar-13, which showed that control mice maintain functional antibody titers, but SCD mice do
not. This data has clinical relevance as a recent study in children with SCD demonstrated their
inability to sustain anti-PPS3 pneumococcal responses one year after Prevnar-13 vaccination,
thus potentially leaving vaccinated children susceptible to infection [21]. This lack of vaccine
“take” has important clinical implications and warrants further investigation into the cellular
and molecular mechanisms driving this failure.
It has been observed that the administration of antibiotics enhances the deposition of complement components on the surface of S. pneumoniae, thereby enhancing protective phagocytic
responses in conjunction with specific anti-pneumococcal antibodies [22, 23, 24]. It has also
been previously shown in SCD patients that have reduced opsonization due to defects in the
alternative complement pathway, which acts in conjunction with impaired anti-pneumococcal
antibody responses to further inhibit opsonization [25]. It is therefore possible that the coadministration of penicillin and pneumococcal vaccination may be acting synergistically to
improve vaccine efficacy in people with SCD. We measured the plasma levels of the complement protein C3 in control and SCD mice, but both groups had normal C3 levels and were not
statistically different from each other (data not shown). However, it may still be possible to
increase pneumococcal vaccine efficacy in the SCD mouse model through the co-administration of penicillin with Prevnar-13 vaccination.
One potential culprit for lack of protection after vaccination and infectious challenge
observed in our model is the well-documented splenic dysfunction and loss of memory IgM/B1 B-cells found in SCD (which are important for generating anti-polysaccharide antibodies).
We have previously shown that these important cells are reduced in proportion in the spleens
of SCD mice when compared to controls and correlate with reduced baseline levels of total
serum IgM and subclasses of IgG [13]. In this study, we found that serum anti-PPS3 IgG3 titers
waned after vaccination, and this subclass of IgG is associated with responses to polysaccharide
antigens and is protective against S. pneumoniae infection [26]. Additionally, antibody titers
increased in SCD mice after initial vaccination, but then waned after subsequent booster shots
and did not recover. These findings indicate that responses from short-lived plasma cells
remain intact in SCD mice; however, long-lived plasma cells do not appear to be generated
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and/or sustained. Plasma cell longevity has been associated with up-regulation of anti-apoptotic genes [27], suggesting these as intriguing targets for further study in B-cells from people
and mice with SCD. Other molecules involved in the long-term differentiation and survival of
plasma cells (such as APRIL or Blimp-1) would be worth investigating as well [28, 29]. We
should also note that Carter et al. [30] found that using pneumococcal proteins as vaccine antigens also did not confer protection to SCD mice upon infectious challenge (whereas some of
the control mice survive). This raises the possibility that SCD mice have immunological
impairments in addition to B-1 cell deficiencies.
In addition to the lack of generation of long-lived plasma cells in young SCD mice after
pneumococcal vaccination, the absence of a booster response indicates that B-cell memory is
also not generated. If such a lack of B-cell memory induction is also observed in SCD patients,
this would warrant the need for more frequent vaccination to ensure that protective antibodies
are maintained. However, the safety of more frequent vaccination has never been tested in children with SCD and should be approached used with caution. Indeed, we have previously found
that vaccination may yield adverse effects in SCD mice [18]. Furthermore, the phenomenon of
B-cell exhaustion has recently been described [31], and it is possible that increasing the frequency in which this population is vaccinated could further contribute to the problem.
Pneumococcal infection is an enormous problem in children with SCD, and the utilization
of prophylactic strategies to prevent infection is essential to prolong the duration and quality of
life in this population. Disturbingly, there have been reports that pneumococcal vaccines may
not be as efficacious in children with SCD when compared to the general population. We utilized a SCD mouse model of pneumococcal vaccination and infection to study this problem
and found that the polysaccharide-conjugate vaccine Prevnar-13 actually has very poor efficacy
in these mice. The reasons for incomplete protection from infection appear to correlate with
their inability to maintain polysaccharide-specific antibody titers. The potential candidates for
this problem are a lack of the generation and/or maintenance of long-lived plasma cells and/or
memory B-cells (likely of B-1 origin). Understanding which correlates of protective immunity
are lacking in SCD mice will be essential so that targeted therapeutics can be developed to
allow for achievement of long-term immunity after vaccination and subsequent reduction of
morbidity and mortality in children with SCD.
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